These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 15233225)
1. The role of modulation of GH/IGF-I axis in the development of diabetic proliferative retinopathy. Genovese S; Riccardi G J Endocrinol Invest; 2003; 26(8 Suppl):114-6. PubMed ID: 15233225 [No Abstract] [Full Text] [Related]
2. [Therapy of diabetic retinopathy with somatostatin analogues]. Lang GE Ophthalmologe; 2004 Mar; 101(3):290-3. PubMed ID: 15007609 [TBL] [Abstract][Full Text] [Related]
4. The therapeutic problem of proliferative diabetic retinopathy: targeting somatostatin receptors. Davis MI; Wilson SH; Grant MB Horm Metab Res; 2001 May; 33(5):295-9. PubMed ID: 11440276 [TBL] [Abstract][Full Text] [Related]
5. Pharmacological treatment of diabetic retinopathy. Lang GE Ophthalmologica; 2007; 221(2):112-7. PubMed ID: 17380065 [TBL] [Abstract][Full Text] [Related]
6. Growth hormone and somatostatin in glomerular injury. Baud L; Fouqueray B; Bellocq A; Doublier S; Dumoulin A J Nephrol; 1999; 12(1):18-23. PubMed ID: 10202998 [TBL] [Abstract][Full Text] [Related]
7. Use of somatostatin receptor ligands in obesity and diabetic complications. Boehm BO; Lustig RH Best Pract Res Clin Gastroenterol; 2002 Jun; 16(3):493-509. PubMed ID: 12079271 [TBL] [Abstract][Full Text] [Related]
8. [Role of insulin-like growth factor I in the development of diabetic retinopathy]. Gacka M; Adamiec J Przegl Lek; 2003; 60(9):588-92. PubMed ID: 15065339 [TBL] [Abstract][Full Text] [Related]
9. Progression of diabetic retinopathy during improved metabolic control may be treated with reduced insulin dosage and/or somatostatin analogue administration -- a case report. Chantelau E; Frystyk J Growth Horm IGF Res; 2005 Apr; 15(2):130-5. PubMed ID: 15809016 [TBL] [Abstract][Full Text] [Related]
10. [Somatostatin analogues: a therapeutic tool in proliferative diabetic retinopathy?]. Vialettes B; Mallet B Journ Annu Diabetol Hotel Dieu; 1992; ():63-70. PubMed ID: 1353800 [No Abstract] [Full Text] [Related]
11. The potential role of octreotide in the treatment of diabetic retinopathy. Grant MB; Caballero S Treat Endocrinol; 2005; 4(4):199-203. PubMed ID: 16053337 [TBL] [Abstract][Full Text] [Related]
12. Somatostatin analogues as drug therapies for retinopathies. Grant MB; Caballero S Drugs Today (Barc); 2002 Nov; 38(11):783-91. PubMed ID: 12582462 [TBL] [Abstract][Full Text] [Related]
13. The role of growth hormone in the pathogenesis of diabetic kidney disease. Flyvbjerg A Pediatr Endocrinol Rev; 2004 Aug; 1 Suppl 3():525-9. PubMed ID: 16444187 [TBL] [Abstract][Full Text] [Related]
14. Use of long-acting somatostatin analogue treatment in diabetic retinopathy. Boehm BO Dev Ophthalmol; 2007; 39():111-121. PubMed ID: 17245082 [TBL] [Abstract][Full Text] [Related]
15. Role of the growth hormone/insulin-like growth factor-1 paracrine axis in rheumatic diseases. Denko CW; Malemud CJ Semin Arthritis Rheum; 2005 Aug; 35(1):24-34. PubMed ID: 16084221 [TBL] [Abstract][Full Text] [Related]
17. Comparison between somatostatin analogues and ACE inhibitor in the NOD mouse model of diabetic kidney disease. Segev Y; Eshet R; Rivkis I; Hayat C; Kachko L; Phillip M; Landau D Nephrol Dial Transplant; 2004 Dec; 19(12):3021-8. PubMed ID: 15494355 [TBL] [Abstract][Full Text] [Related]
18. [Assessment of growth factor levels in adolescents with type 1 diabetes mellitus and the beginning of diabetic microangiopathy]. Peczyńska J; Urban M; Urban B; Głowińska B; Florys B Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2004; 10(1):41-8. PubMed ID: 15355738 [TBL] [Abstract][Full Text] [Related]
19. The role of growth hormone, insulin-like growth factor and somatostatin in diabetic retinopathy. Wilkinson-Berka JL; Wraight C; Werther G Curr Med Chem; 2006; 13(27):3307-17. PubMed ID: 17168853 [TBL] [Abstract][Full Text] [Related]